1-4 of 4
Can Hekim
Close
Sort by
Journal Articles

Combining nilotinib and PD-L1 blockade reverses CD4 + T-cell dysfunction and prevents relapse in acute B-cell leukemia

Sean I. Tracy, Hrishi Venkatesh, Can Hekim, Lynn M. Heltemes-Harris, Todd P. Knutson, Veronika Bachanova, Michael A. Farrar
Journal: Blood
Blood (2022) 140 (4): 335–348.
https://doi.org/10.1182/blood.2021015341
Published: 2022
Includes: Supplemental data
Journal Articles

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

Sean I. Tracy, MD PhD, Can Hekim, MSc,PhD, Michael Farrar, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1345.
https://doi.org/10.1182/blood-2019-124205
Published: 2019
Journal Articles

Overcoming Leukemia-Induced Immune Suppression in BCR-ABL+ Acute Lymphoblastic Leukemia

Michael Farrar, PhD, Can Hekim, MSc,PhD, Manlove S. Luke, PhD, Vaiva Vezys, PhD, Marc K Jenkins, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3881.
https://doi.org/10.1182/blood.V130.Suppl_1.3881.3881
Published: 2017
Journal Articles

Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model

Mette Matilda Ilander, MSc, Can Hekim, PhD, Markus Vähä-Koskela, PhD, Paula Savola, Siri Tähtinen, MSc, Leena Saikko, Akseli Hemminki, MDPhD, Panu Kovanen, MDPhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD
Journal: Blood
Blood (2014) 124 (21): 1408.
https://doi.org/10.1182/blood.V124.21.1408.1408
Published: 2014